Study of ARO-APOC3 in Adults With Mixed Dyslipidemia

PHASE2CompletedINTERVENTIONAL
Enrollment

353

Participants

Timeline

Start Date

September 28, 2021

Primary Completion Date

February 10, 2023

Study Completion Date

August 14, 2023

Conditions
Mixed Dyslipidemia
Interventions
DRUG

ARO-APOC3

ARO-APOC3 Injection

DRUG

Placebo

Sterile Normal Saline (0.9% NaCl)

Trial Locations (30)

2025

Research Site 11, Auckland

3168

Research Site 19, Clayton

4506

Research Site 30, Morayfield

5000

Research Site 29, Adelaide

6027

Research Site 27, Joondalup

8013

Research Site 16, Christchurch

12553

Research Site 17, New Windsor

29607

Research Site 7, Greenville

30338

Research Site 18, Dunwoody

33024

Research Site 5, Pembroke Pines

33166

Research Site 14, Miami Springs

33308

Research Site 1, Fort Lauderdale

33434

Research Site 2, Boca Raton

45005

Research Site 4, Franklin

45419

Research Site 12, Dayton

77002

Research Site 6, Houston

77030

Research Site 32, Houston

78249

Research Site 13, San Antonio

89121

Research Site 31, Las Vegas

90211

Research Site 3, Beverly Hills

91325

Research Site 8, Northridge

L4K 4M2

Research Site 15, Concord

H2W2T2

Research Site 10, Montreal

H-8230

Research Site 20, Balatonfüred

H-4032

Research Site 21, Debrecen

H-4405

Research Site 22, Nyíregyháza

93-338

Research Site 28, Lodz

94-048

Research Site 24, Lodz

61-655

Research Site 25, Poznan

35-055

Research Site 26, Rzeszów

Sponsors
All Listed Sponsors
lead

Arrowhead Pharmaceuticals

INDUSTRY